Skip to content Skip to footer
Subscribe Now
PharmaShots Interview Medicago’s Brian Ward Shares Insights on COVIFENZ, a Plant-Based COVID-19 Vaccine
VIEWPOINTS

PharmaShots Interview: Medicago’s Brian Ward Shares Insights on COVIFENZ, a Plant-Based COVID-19 Vaccine

In an interview with PharmaShots, Brian Ward, CEO at Medicago shared his views on the approval of a Plant-Based COVID-19 Vaccine in combination with GSK’s pandemic adjuvant Shots: Brian talked about the data that supported the approval of Medicago’s plant-based Covid-19 vaccine by Health Canada He focused on the safety and efficacy of the vaccine…
May 25, 2022

Read more

PharmaShots Interview Medicago’s Brian Ward Shares Insights on the Data of Plant-Based COVID-19 Vaccine
VIEWPOINTS

PharmaShots Interview: Medicago’s Brian Ward Shares Insights on the Data of Plant-Based COVID-19 Vaccine

In an interview with PharmaShots, Brian Ward, Medical Officer at Medicago shares his views on the P-III study of plant-based COVID-19 vaccine in combination with GSK’s pandemic adjuvant for the treatment of COVID-19  Shots: The company reported efficacy and safety results from the P-III study of Medicago’s plant-based COVID-19 vaccine candidate + GSK’s pandemic adjuvant in ~24,000 adults aged ≥18yrs. across Canada, US, UK,…
January 12, 2022

Read more

Viewpoints_Nathalie Landry
VIEWPOINTS

PharmaShots Interview: Medicago’s Nathalie Landry Shares Insights on the Phase 2 Results of Plant-Based COVID-19 Vaccine

In an Interview with PharmaShots, Nathalie Landry, Executive Vice President, Scientific, and Medical Affairs at Medicago share her views on the P-II results of adjuvanted plant-based COVID-19 vaccine. Shots: The P-II study involves assessing the safety & immunogenicity of the CoVLP vs PBO in 306 subjects aged =18yrs. with two age groups (18-64yrs & over 65yrs.) across…
June 29, 2021

Read more